Masakazu Toi

Oncology · 2000–2021

A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Oncology — 70 citations into it; #1,656 of 1,698 by trust here, #650 by citations
• Molecular Biology — 16 citations into it; #17,469 of 17,773 by trust here, #15,850 by citations

Whom Masakazu Toi trusts

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Adams (in Molecular Biology)

Who trusts Masakazu Toi

1. M. Karin (in Cancer Research)

Papers from Masakazu Toi's perspective

Ordered by how strongly the researchers Masakazu Toi trusts endorse each paper. Same corpus, a different order for every researcher.

1. A phase 2 study of bortezomib in relapsed, refractory myeloma. (New England Journal of Medicine)
2. Signaling to NF-kappaB. (Genes & Development)
3. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. (Journal of Clinical Oncology)
4. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (Journal of the National Cancer Institute)
5. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB (Nature)
6. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. (Journal of Clinical Oncology)
7. The proteasome: a suitable antineoplastic target (Nature Reviews. Cancer)
8. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (JAMA Oncology)
9. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (npj Breast Cancer)
10. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. (Journal of the National Cancer Institute)

Their papers

• Nuclear factor-κB inhibitors as sensitizers to anticancer drugs (2005) — 716 citations
• Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) — 687 citations
• Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (2020) — 820 citations
• The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (2019) — 846 citations
• MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (2019) — 607 citations
• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) — 862 citations
• MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. (2017) — 1,431 citations
• MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (2017) — 1,439 citations
• Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy (2017) — 1,559 citations
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) — 3,678 citations
• Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. (2000) — 780 citations